Search

Your search keyword '"De La Hoya, Miguel"' showing total 817 results

Search Constraints

Start Over You searched for: Author "De La Hoya, Miguel" Remove constraint Author: "De La Hoya, Miguel"
817 results on '"De La Hoya, Miguel"'

Search Results

1. Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel

2. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

3. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

4. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants

5. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium

6. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

7. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

8. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

9. A New Set of in Silico Tools to Support the Interpretation of ATM Missense Variants Using Graphical Analysis

10. Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia

11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

12. Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

13. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

14. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

15. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

16. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

17. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.

18. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants

19. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.

20. BRCA2 gene mutations and coagulation-associated biomarkers

21. Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel

22. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

23. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

24. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

25. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.

26. Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

27. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.

28. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.

29. Comprehensive splicing analysis of the alternatively spliced CHEK2 exons 8 and 10 reveals three enhancer/silencer‐rich regions and 38 spliceogenic variants.

30. A New Set of in Silico Tools to Support the Interpretation of ATM Missense Variants Using Graphical Analysis

31. Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants

33. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

34. Supplementary Figures and Table from BRIP1, a Gene Potentially Implicated in Familial Colorectal Cancer Type X

35. Data from BRIP1, a Gene Potentially Implicated in Familial Colorectal Cancer Type X

37. Supplementary Table 2 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

38. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

39. Supplementary Table 3 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

40. Data from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

41. Supplementary Tables 1-9 from Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

42. Supplementary Data from Analysis of the Oxidative Damage Repair Genes NUDT1, OGG1, and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC)

43. Data from Analysis of the Oxidative Damage Repair Genes NUDT1, OGG1, and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC)

44. Data from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

45. Supplementary Methods, Tables 1-3, Figure 1 from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

46. Abstract P6-02-15: Don’t get lost in translation: Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) recommendations for reporting germline cancer susceptibility gene variants in 19 languages – breast cancer as a model

47. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

48. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

50. Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing

Catalog

Books, media, physical & digital resources